• Exchange: Toronto
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

Trimel Pharmaceuticals Corp

+ Add to Watchlist


0.6850 CAD 0.0150 2.24%

As of 15:59:40 ET on 04/16/2014.

Snapshot for Trimel Pharmaceuticals Corp (TRL)

Open: 0.6700 Day's Range: 0.6700 - 0.6900 Volume: 36,574
Previous Close: 0.6700 52wk Range: 0.3300 - 1.2400 1-Yr Rtn: -24.73%

Stock Chart for TRL

No chart data available.
  • TRL:CN 0.6900
  • 1D
  • 1M
  • 1Y
Interactive TRL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for TRL

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPTSX -
Earnings Per Share (USD) (ttm) -0.2580
Est. EPS (USD) (12/2014) -0.1330
Est. PEG Ratio -
Market Cap (M CAD) 111.74
Shares Outstanding (M) 163.13
30 Day Average Volume 373,311
Price/Book (mrq) 3.2743
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/08/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for TRL

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for TRL

Trimel Pharmaceuticals Corp. is a pharmaceutical development company. The Company's primary objective is to exploit Trimel's drug-delivery technology portfolio and to target unmet medical needs in underserved disease states. Trimel's term objectives include the development of products for the treatment of male hypogonadism, female sexual dysfunction, and Parkinson's disease.

Tom RossiPresident/CEO/COOKenneth G HowlingChief Financial Officer
Nathan John BrysonVP:Scientific Affairs
More Company Profile & Key Executives for TRL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Links
sec ||= nil